S
Rich Tillyer
Senior Vice President, Worldwide Preclinical Development, Merck
CAREER JOLT: Moved to Manufacturing
YOU DIDN'T KNOW: "I can't swim"
As the head of preclinical development, Rich Tillyer has helped lead Merck's radical redesign of its storied R&D establishment. In this overturning of tradition, his youth—and abundant British charm—have played a critical role. "I think younger leaders are much better at connecting with employees, so that folks can understand the macro decisions we make," he says. "But we also work to keep folks motivated and focused on their mission."
Rich Tillyer
Like other young stars, Tillyer credits his passion in the lab for his fast rise. But in fact, his capacity to embrace change may have been the decisive factor. His biggest break came disguised as his biggest disruption. Six years in and still a self-described "immature chemist," he was yanked out of the lab and installed as support for the president of the manufacturing division. "At first I was reluctant. Here were these big executives and I was running meetings for them," he recalls. But the two-year stint provided a crash course "in what manufacturing's all about, including the marketing and regulatory aspects."
Once back in the lab, he began integrating—gasp!—cost-effectiveness.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.